Clinical Trials Directory

Trials / Completed

CompletedNCT00616018

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days

Acetaminophen Adduct Formation in Alcohol Abstaining Subjects Administered Therapeutic Doses of Acetaminophen for Ten Consecutive Days

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Kennon Heard · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver. The protein-acetaminophen product is called an "adduct." After a large acetaminophen overdose, the liver has to process a lot of acetaminophen, so large amounts of adducts are formed. However, we have found that lower levels may be formed even when people take recommended doses. The purpose of this study is to measure the amount of adducts formed when healthy people who do not drink alcohol take normal doses of acetaminophen for 10 days.

Conditions

Interventions

TypeNameDescription
DRUGacetaminophen4 g/day for 10 consecutive days

Timeline

Start date
2007-08-01
Primary completion
2008-01-01
Completion
2008-01-01
First posted
2008-02-14
Last updated
2012-07-12
Results posted
2012-07-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00616018. Inclusion in this directory is not an endorsement.

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days (NCT00616018) · Clinical Trials Directory